Glucagon analogues

US9180169B2 · kind B2 · utility

Assignee

• Zealand Pharma A/S · DK

Inventors

• Jakob Lind Tolborg · Avenue Madeleine, DK
• Keld Fosgerau · Copenhagen, DK
• Pia Nørregaard · Taastrup, DK
• Rasmus JUST · Copenhagen, DK
• Ditte Riber · Copenhagen, DK
• Dieter Hamprecht · Verona, IT
• Robert AUGUSTIN · Ingelheim am Rhein, DE
• Leo Thomas · Biberach, DE
• Wolfgang Rist · Ingelheim am Rhein, DE

Key dates

• Filing date: Sep 17, 2013
• Grant date: Nov 10, 2015
• Expiry date: Sep 17, 2033

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.